379 related articles for article (PubMed ID: 11901288)
21. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.
Robin AL; Ritch R; Shin D; Smythe B; Mundorf T; Lehmann RP
Trans Am Ophthalmol Soc; 1995; 93():421-38; discussion 439-41. PubMed ID: 8719690
[TBL] [Abstract][Full Text] [Related]
22. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.
Liu CJ; Ko YC; Cheng CY; Chiu AW; Chou JC; Hsu WM; Liu JH
Ophthalmology; 2002 Dec; 109(12):2241-7. PubMed ID: 12466165
[TBL] [Abstract][Full Text] [Related]
23. Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma.
Nishimoto JH; Chang FW; Tang IH; Kolin T
J Am Optom Assoc; 1999 Apr; 70(4):233-9. PubMed ID: 10457699
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group.
Stewart WC; Ritch R; Shin DH; Lehmann RP; Shrader CE; van Buskirk EM
Arch Ophthalmol; 1995 Mar; 113(3):287-92. PubMed ID: 7887841
[TBL] [Abstract][Full Text] [Related]
25. Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteers.
Yüksel N; Güler C; Caglar Y; Elibol O
Int Ophthalmol; 1992 Sep; 16(4-5):337-42. PubMed ID: 1358852
[TBL] [Abstract][Full Text] [Related]
26. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension.
Carlsson AM; Chauhan BC; Lee AA; LeBlanc RP
Am J Ophthalmol; 2000 Mar; 129(3):297-301. PubMed ID: 10704543
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans.
Schadlu R; Maus TL; Nau CB; Brubaker RF
Arch Ophthalmol; 1998 Nov; 116(11):1441-4. PubMed ID: 9823343
[TBL] [Abstract][Full Text] [Related]
28. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.
Katz LJ
Am J Ophthalmol; 1999 Jan; 127(1):20-6. PubMed ID: 9932994
[TBL] [Abstract][Full Text] [Related]
29. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I.
Javitt JC; Schiffman RM
J Glaucoma; 2000 Jun; 9(3):224-34. PubMed ID: 10877373
[TBL] [Abstract][Full Text] [Related]
30. A short term study of the additive effect of timolol and brimonidine on intraocular pressure.
Arici MK; Sayici M; Toker M; Erdoğan H; Topalkara A
Eye (Lond); 2002 Jan; 16(1):39-43. PubMed ID: 11913886
[TBL] [Abstract][Full Text] [Related]
31. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy.
Sponsel WE; Paris G; Trigo Y; Pena M; Weber A; Sanford K; McKinnon S
Am J Ophthalmol; 2002 Jan; 133(1):11-8. PubMed ID: 11755835
[TBL] [Abstract][Full Text] [Related]
32. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
[TBL] [Abstract][Full Text] [Related]
33. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.
Melamed S; David R
Clin Ther; 2000 Jan; 22(1):103-11. PubMed ID: 10688394
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
[TBL] [Abstract][Full Text] [Related]
35. Effects of acute topical administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2% on visual field parameters and ocular perfusion pressure in patients with primary open-angle glaucoma.
Sebastiani A; Parmeggiani F; Costagliola C; Ciancaglini M; D'Oronzo E; Mastropasqua L
Acta Ophthalmol Scand Suppl; 2002; 236():29-30. PubMed ID: 12390124
[No Abstract] [Full Text] [Related]
36. Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension.
Sharpe ED; Day DG; Beischel CJ; Rhodes JS; Stewart JA; Stewart WC
Br J Ophthalmol; 2004 Jul; 88(7):953-6. PubMed ID: 15205246
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
[TBL] [Abstract][Full Text] [Related]
39. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II.
Javitt J; Goldberg I
J Glaucoma; 2000 Oct; 9(5):398-408. PubMed ID: 11039742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]